Skip to main content

Advertisement

SpringerLink
Log in

New Goals and Strategies of Chinese Medicine in Prevention and Treatment of Chronic Kidney Disease

  • Feature Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD) is a clinical syndrome with a series of clinical manifestations and metabolic disorders caused by many diseases, which are characterized by progressive deterioration or irreversible damage of renal structures and functions. With the progress of epidemiological research, CKD has brought about huge economic and psychological burdens. There is a considerable risk of cardiovascular events or death than progression to end-stage renal disease for patients. Particular attentions should be paid to the new goals of reducing cardiovascular events and all-cause mortality. It is important to analyze the etiology and pathogenesis according to patients’ ages, regions, primary disease as well as different stages of disease, and choose the appropriate therapeutic strategies accordingly. In clinical practice, due to the uncertainty of therapeutic effects of modern medicine based on the risk factors, it is necessary to use Chinese medicine (CM) to delay the disease progression and reduce comorbidities. Turbid toxin and blood stasis are two critical pathological factors worthy of concerns in the theory of CM. In addition, appropriate use of CM may help improve the quality of life of patients with CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fernandezprado R, Esteras R, Perezgomez MV, Graciaiguacel C, Gonzalezparra E, Sanz AB, et al. Nutrients turned into toxins: microbiota modulation of nutrient properties in chronic kidney disease. Nutrients 2017;9:e489.

    Article  CAS  Google Scholar 

  2. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet 2017;389:1238–1252.

    Article  PubMed  Google Scholar 

  3. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow–up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Int Med 2004;164:659–663.

    Article  Google Scholar 

  4. Nogueira PC, Paz IP. Signs and symptoms of developmental abnormalities of the genitourinary tract. J Pediatr (Rio J) 2016;92(3 Suppl 1):S57–S63.

    Article  Google Scholar 

  5. Happé H, de Heer E, Peters DJM. Polycystic kidney disease: the complexity of planar cell polarity and signaling during tissue regeneration and cyst formation. Biochim Biophys Acta 2011;1812:1249–1255.

    Article  PubMed  CAS  Google Scholar 

  6. Vehaskari VM. Genetics and CKD. Adv Chron Kidney Dis 2011;18:317–323.

    Article  Google Scholar 

  7. Glassock RJ, Rule AD. Aging and the kidneys: anatomy, physiology and consequences for defining chronic kidney disease. Nephron 2016;134:25–29.

    Article  PubMed  Google Scholar 

  8. Morton RL, Schlackow I, Mihaylova B, Staplin ND, Gray A, Cass A. The impact of social disadvantage in moderateto–severe chronic kidney disease: an equity–focused systematic review. Nephrol Dial Transplant 2016;31:46–56.

    Article  PubMed  Google Scholar 

  9. Mahmoodpoor F, Rahbar S Y, Barzegari A, Ardalan M, Zununi VS. The impact of gut microbiota on kidney function and pathogenesis. Biomed Pharmacother 2017;93:412–419.

    Article  PubMed  CAS  Google Scholar 

  10. Koye DN, Magliano DJ, Reid CM, Jepson C, Feldman HI, Herman WH, et al. Risk of progression of nonalbuminuric CKD to end–stage kidney disease in people with diabetes: the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis 2018;72:653–661.

    Article  PubMed  Google Scholar 

  11. Riella MC. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Intl Suppl 2013;3:1–150.

    Google Scholar 

  12. Li S, Rao XR, Dai XW, Pei K, Wang L, Huo BM, et al. Beneficial effects of Fu–Zheng–Qu–Zhuo Oral Liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3–4): a randomized placebocontrolled clinical trial. Medicine (Baltimore) 2017;96:e7448.

    Article  Google Scholar 

  13. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003;108:2154–2169.

    Article  PubMed  Google Scholar 

  14. Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014;85:1303–1309.

    Article  PubMed  CAS  Google Scholar 

  15. Appel LJ, Wright JJ, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood–pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363:918–929.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45(4 Suppl 3):S1–S153.

    Google Scholar 

  17. Major RW, Oozeerally I, Dawson S, Riddleston H, Gray LJ, Brunskill NJ. Aspirin and cardiovascular primary prevention in non–end stage chronic kidney disease: a meta–analysis. Atherosclerosis 2016;251:177–182.

    Article  PubMed  CAS  Google Scholar 

  18. Lekawanvijit S. Cardiotoxicity of uremic toxins: a driver of cardiorenal syndrome. Toxins (Basel) 2018;10:e352.

    Article  CAS  Google Scholar 

  19. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934–1943.

    Article  PubMed  CAS  Google Scholar 

  20. Nasri H, Mubarak M. Significance of vasculopathy in IgA nephropathy patients with regard to Oxford classification and immunostaining findings: a single center experience. J Renal Inj Prev 2013;2:41–45.

    PubMed  PubMed Central  Google Scholar 

  21. Li S, Rao XR, Wang SX, Zhang GH, Li XM, Dai XW, et al. Study on the relationship between blood stasis syndrome and clinical pathology in 227 patients with primary glomerular disease. Chin J Integr Med 2009;15:170–176.

    Article  PubMed  Google Scholar 

  22. Okubo R, Kai H, Kondo M, Saito C, Yoh K, Morito N, et al. Health–related quality of life and prognosis in patients with chronic kidney disease: a 3–year follow–up study. Clin Exp Nephrol 2014;18:697–703.

    Article  PubMed  Google Scholar 

  23. Etgen T, Chonchol M, Forstl H, Sander D. Chronic kidney disease and cognitive impairment: a systematic review and meta–analysis. Am J Nephrol 2012;35:474–482.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China

    Chuan Guo, Shen Li & Xiang-rong Rao

Authors
  1. Chuan Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiang-rong Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiang-rong Rao.

Additional information

Supported by the National Natural Science Foundation of China (No. 81573791, 81141122), and Special Research Project in Chinese Medicine Industry (No. 201407001)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, C., Li, S. & Rao, Xr. New Goals and Strategies of Chinese Medicine in Prevention and Treatment of Chronic Kidney Disease. Chin. J. Integr. Med. 25, 163–167 (2019). https://doi.org/10.1007/s11655-019-3065-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-019-3065-z

Keywords

Search

Navigation